Table 1 Patient pathologic, pre-treatment, and treatment characteristics

Age Median (IQR)

65.5 (59.4-70.2)

62.8 (58.6-68.6)

p=0.14*

CCMI Median (IQR)

3.0 (3.0-4.0)

3.0 (3.0-4.0)

p=0.2*

Range

1.0-8.0

1.0-7.0

Pre-SRT PSA Median (IQR)

0.6 (0.4-1.1)

0.8 (0.5-1.75)

p<0.001*

Range

0.1-6.3

0.2-17.4

SRT dose Median (IQR)

68.4 (64.8-68.4)

68.4 (64.8-68.4)

p=0.05*

WPRT

11.4%

6.9%

p=0.3**

ADT during SRT

12.5%

18.8%

p=0.2**

ADT duration

5.9 (4.4-8.5)

6.1 (4.7-15.1)

p=0.6*

Gleason score

2-6

22.2%

11.9%

p=0.02**

7

61.4%

60.4%

8-10

16.5%

27.7%

pTstage

T1-T2a

13.0%

6.3%

p=0.15**

T2b-T2c

32.2%

27.5%

T3-T4

54.8%

66.3%

SVI

9.8%

16.8%

p=0.13**

ECE

45.4%

52.5%

p=0.3**

SM

43.2%

44.0%

p=0.9**

LNI

2.1%

1.2%

p=0.9**